Read more

Twitter Grows its Patent Portfolio via Acquisitions

We last reported on Twitter’s patenting efforts back in 2013, when the company had announced its patent pledge.  At the time, Twitter owned only two issued patents. Since then, the company’s patent portfolio has grown tremendously, thanks mostly in part to Twitter’s acquisition of over 900 patents from IBM in 2014. The IBM patent acquisition was a […]

Read more

Future of Sidecar May Lie in its Patent Portfolio

Sidecar announced today that it is licensing its patent assets to General Motors. While Sidecar was founded in 2011, the company’s co-founder Sunil Paul developed and patented ridesharing technology more than a decade earlier. Paul received US 6,356,838 in 2002, based on a patent application he filed in 2000. The ‘838 patent has been widely reported in the media, as […]

Read more

Xiaomi Diligently Filing US Patent Applications

Less than a year ago, Chinese smartphone maker Xiaomi Corp. closed a $1.1 billion round of funding, valuing the company at over $45 billion. While Xiaomi is known for its smartphones, the company also has a number of service-oriented business lines, from mobile gaming and entertainment, to electronic payments.  Given the immense valuation of the company, […]

Read more

Microsoft Has a Diverse Software Focused Patent Portfolio

Earlier this month, Microsoft and Google announced a settlement to end nearly 20 patent-related lawsuits in the U.S. and Germany. The deal brought to close years of patent litigation surrounding various technologies, including gaming systems, mobile devices, and multimedia streaming. Envision IP analyzed Microsoft’s US patent portfolio to understand where the company has focused its […]

Read more

Challenge the Patent and Short the Stock – Does it Really Work?

The Coalition for Affordable Drugs has been the subject of much controversy in recent months. The organization is backed by hedge fund billionaire Kyle Bass and Hayman Capital, who are using inter partes review filings (IPR) to challenge patents of public pharmaceutical companies. The ultimate goal for Bass and Hayman Capital presumably being to profit […]